Summary
GlobalData's Medical Devices sector report, “Insulin Pens - Medical Devices Pipeline Assessment, 2016" provides an overview of Insulin Pens currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Insulin Pens pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Insulin Pens under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Insulin Pens and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Insulin Pens under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Companies Mentioned
Becton, Dickinson and Company
Calibra Medical, Inc.
Cambridge Consultants Limited
Companion Medical, Inc.
Emperra GmbH E-Health Technologies
MedPro Safety Products, Inc.
MicroPort Scientific Corporation
Sanofi
'
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 Insulin Pens Overview 6
3 Products under Development 7
3.1 Insulin Pens - Pipeline Products by Stage of Development 7
3.2 Insulin Pens - Pipeline Products by Segment 8
3.3 Insulin Pens - Pipeline Products by Territory 9
3.4 Insulin Pens - Pipeline Products by Regulatory Path 10
3.5 Insulin Pens - Pipeline Products by Estimated Approval Date 11
4 Insulin Pens - Pipeline Products under Development by Companies 12
4.1 Insulin Pens Companies - Pipeline Products by Stage of Development 12
4.2 Insulin Pens - Pipeline Products by Stage of Development 13
5 Insulin Pens Companies and Product Overview 14
5.1 Becton, Dickinson and Company Company Overview 14
5.1.1 Becton, Dickinson and Company Pipeline Products & Ongoing Clinical Trials Overview 14
5.2 Calibra Medical, Inc. Company Overview 16
5.2.1 Calibra Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 16
5.3 Cambridge Consultants Limited Company Overview 17
5.3.1 Cambridge Consultants Limited Pipeline Products & Ongoing Clinical Trials Overview 17
5.4 Companion Medical, Inc. Company Overview 19
5.4.1 Companion Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19
5.5 Emperra GmbH E-Health Technologies Company Overview 20
5.5.1 Emperra GmbH E-Health Technologies Pipeline Products & Ongoing Clinical Trials Overview 20
5.6 MedPro Safety Products, Inc. Company Overview 22
5.6.1 MedPro Safety Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview 22
5.7 MicroPort Scientific Corporation Company Overview 23
5.7.1 MicroPort Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
5.8 Sanofi Company Overview 25
5.8.1 Sanofi Pipeline Products & Ongoing Clinical Trials Overview 25
6 Insulin Pens- Recent Developments 27
6.1 Mar 23, 2016: B. Braun's growth trend continues 27
6.2 Mar 10, 2016: Sanofi Appoints Dr. Ameet Nathwani to Executive Committee and Executive Vice President, Group Chief Medical Officer 28
6.3 Mar 08, 2016: Antares Pharma Reports Fourth Quarter and Full Year 2015 Operating and Financial Results 28
6.4 Mar 07, 2016: InsuLine Medical to Raise Funds in Financing Round 30
6.5 Feb 09, 2016: Sanofi Delivered 2015 Business EPS Up 8.5% On A Reported Basis And Stable At Constant Exchange Rates Consistent With Guidance 30
6.6 Feb 04, 2016: Sanofi India Announces Results for the Quarter & Year Ended December 31, 2015 38
6.7 Feb 03, 2016: BD Announces Results For 2016 First Fiscal Quarter 38
6.8 Jan 26, 2016: Antares Pharma Announces CEO Transition 39
6.9 Jan 21, 2016: U.S. Food and Drug Administration Approves Humulin R U-500 KwikPen 40
6.10 Jan 21, 2016: Singularity University and BD Announce Collaboration Dedicated to Address Global Healthcare Challenges 40
6.11 Jan 21, 2016: Biocon Q3FY16 Net Profit Up 13% at Rs 103 Crore, EBITDA Increases 23% to Rs 209 Crore, Revenues at Rs 857 Crore, up by 10% 41
6.12 Jan 11, 2016: Insulet Enters into Co-Development Agreement with Eli Lilly 44
6.13 Jan 05, 2016: Ypsomed Enters into Distribution Agreement with Tonghua Dongbao Pharma 44
6.14 Dec 04, 2015: Change in B. Braun Management Board 44
6.15 Dec 01, 2015: Owen Mumford Launches New Touch Activated Lancet 44
6.16 Nov 20, 2015: Sanofi India Announces Sale of Building in Andheri, Mumbai 45
6.17 Nov 05, 2015: Antares Pharma Reports Third Quarter 2015 Operating and Financial Results 45
6.18 Nov 04, 2015: BD Announces Results For 2015 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2016 Guidance 46
6.19 Oct 20, 2015: Sanofi India - Outcome of Board Meeting 48
6.20 Oct 20, 2015: Sanofi India Announces Q3 results & Limited Review Report for the quarter ended September 30, 2015 48
6.21 Sep 22, 2015: Novo Nordisk and the Food and Drug Administration of the Islamic Republic of Iran sign memorandum of understanding to build manufacturing facility in Iran 48
6.22 Sep 16, 2015: Sanofi's CSR Achievements Recognized In The Dow Jones Sustainability Indices 49
6.23 Sep 15, 2015: Biocon Inaugurates World Class Devices Facility & Introduces Basalog One 49
6.24 Sep 15, 2015: Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 50
6.25 Sep 15, 2015: Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 50
6.26 Sep 15, 2015: BD Named 2015 Outstanding Corporate Innovator Winner by Product Development and Management Association 50
6.27 Sep 15, 2015: Biocon Inaugurates World Class Devices Facility 51
6.28 Aug 24, 2015: Biocon Clarifies On FDA’s Inspection 51
6.29 Aug 18, 2015: Lilly's Humalog 200 units/mL KwikPen Now Available in U.S. Pharmacies 51
6.30 Aug 10, 2015: Antares Pharma Reports Second Quarter 2015 Operating and Financial Results 52
6.31 Aug 06, 2015: BD Announces Results for 2015 Third Fiscal Quarter and Raises EPS Guidance for Fiscal 2015 53
6.32 Jul 30, 2015: Sanofi delivers solid sales and business EPS(1) growth in Q2 2015 55
6.33 Jul 23, 2015: Biocon's Earnings Surge in Q1 FY16; Revenue up by 15% at Rs. 857 Crore, Net Profit up by 23% at Rs. 126 Crore 62
6.34 Jul 23, 2015: Appointment of Chief Financial Officer : Sanofi India 63
6.35 Jul 21, 2015: Sanofi India Announces Q2 results 63
6.36 Jul 15, 2015: Sanofi Announces New, Global Business Unit Structure To Drive Future Growth 64
6.37 Jul 15, 2015: BD Opens Advance Diabetes Care Headquarters in Andover, Mass. 64
6.38 Jul 14, 2015: Antares Pharma Appoints Peter J. Graham Esq., Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer and Corporate Secretary 65
6.39 Jul 13, 2015: BD Announces Sustainability Goals for 2020 65
6.40 Jul 09, 2015: Gerresheimer substantially improves operating earnings in second quarter 66
6.41 Jul 08, 2015: BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 67
6.42 Jul 01, 2015: Haselmeier Group Announces the Extension and Reorganization of its Executive Board 67
6.43 Jun 30, 2015: Ypsomed now supplies the YpsoPen in Poland 68
6.44 Jun 24, 2015: EMPERRA's Bluetooth-enabled ESYSTA Smart Insulin Pen in the Last Stages of the CE Approval Process 68
6.45 Jun 06, 2015: New Clinical Data Suggest Infusion Set with BD FlowSmart Technology May Improve Insulin Flow and Reduce Silent Occlusions 70
6.46 Jun 02, 2015: BD Participates in White House Forum on Antibiotic Stewardship 71
6.47 May 27, 2015: U.S. Food and Drug Administration Approves Humalog 200 units/mL KwikPen 71
6.48 May 21, 2015: Haselmeier receives prestigious accolade for two of their products: The international GOOD DESIGN Award 2014 72
6.49 May 20, 2015: Companion Medical Raises USD3.15 Million in Series B Financing 72
6.50 May 18, 2015: Haselmeier Group Announces the Relocation of Haselmeier in the United States 73
6.51 May 15, 2015: Sanofi Announces Departure Of Chief Strategy Officer 73
6.52 May 13, 2015: DuBiotech Welcomes Germany’s B.Braun 73
6.53 May 11, 2015: Antares Pharma Reports First Quarter 2015 Operating and Financial Results 74
6.54 May 11, 2015: Antares Pharma Reports First Quarter 2015 Financial and Operating Results 75
6.55 May 07, 2015: BD Announces Results For 2015 Second Fiscal Quarter 77
6.56 May 07, 2015: Biocon-Mylan Programs Make Progress: PEG-G-CSF and Adalimumab enter Phase 3 clinical trials; Patient recruitment for one Insulin Glargine Phase 3 study completed 78
7 Appendix 79
7.1 Methodology 79
7.2 About GlobalData 81
7.3 Contact Us 82
7.4 Disclaimer 82
1.1 List of Tables
Table 1: Insulin Pens - Pipeline Products by Stage of Development 7
Table 2: Insulin Pens - Pipeline Products by Segment 8
Table 3: Insulin Pens - Pipeline Products by Territory 9
Table 4: Insulin Pens - Pipeline Products by Regulatory Path 10
Table 5: Insulin Pens - Pipeline Products by Estimated Approval Date 11
Table 6: Insulin Pens Companies - Pipeline Products by Stage of Development 12
Table 7: Insulin Pens - Pipeline Products by Stage of Development 13
Table 8: Becton, Dickinson and Company Pipeline Products & Ongoing Clinical Trials Overview 14
Table 9: Next Generation Pen Needle II - Product Status 15
Table 10: Next Generation Pen Needle II - Product Description 15
Table 11: Calibra Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 16
Table 12: Pre-Filled Insulin Device - Product Status 16
Table 13: Pre-Filled Insulin Device - Product Description 16
Table 14: Cambridge Consultants Limited Pipeline Products & Ongoing Clinical Trials Overview 17
Table 15: KiCoPen - Product Status 18
Table 16: KiCoPen - Product Description 18
Table 17: Companion Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19
Table 18: Insulin Pen - Product Status 19
Table 19: Insulin Pen - Product Description 19
Table 20: Emperra GmbH E-Health Technologies Pipeline Products & Ongoing Clinical Trials Overview 20
Table 21: Bluetooth-enabled ESYSTA Smart Insulin Pen - Product Status 21
Table 22: Bluetooth-enabled ESYSTA Smart Insulin Pen - Product Description 21
Table 23: MedPro Safety Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview 22
Table 24: Insulin Guard Self-Injector Safety Needle - Product Status 22
Table 25: Insulin Guard Self-Injector Safety Needle - Product Description 22
Table 26: MicroPort Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
Table 27: La Fenice Pen - Product Status 24
Table 28: La Fenice Pen - Product Description 24
Table 29: Sanofi Pipeline Products & Ongoing Clinical Trials Overview 25
Table 30: Fix-Flex Device - Product Status 26
Table 31: Fix-Flex Device - Product Description 26
Table 32: Glossary 80
1.2 List of Figures
Figure 1: Insulin Pens - Pipeline Products by Stage of Development 7
Figure 2: Insulin Pens - Pipeline Products by Segment 8
Figure 3: Insulin Pens - Pipeline Products by Territory 9
Figure 4: Insulin Pens - Pipeline Products by Regulatory Path 10
Figure 5: Insulin Pens - Pipeline Products by Estimated Approval Date 11
